Inhibition of normal glycolysis in tumor cells through targeting SGLT2 may provide a starting point for exploring the potential of empagliflozin as a dual-use drug for the treatment of patients with diabetes and cancer, but further research is needed to provide more detailed data to support this potential use of empagliflozin. This evidence concerns the gene SLC5A2 and diabetes mellitus.